Date:5/31/2011

ales symposium, the sales team has been reviewing all available literature, technical details and benefits of the test.  This has involved Company experts, external medical faculty and key opinion leaders.  Speakers are part of a more extensive Key Opinion Leader network the company has been building over the last 12 months.  Located in leading oncology institutions, this network of practicing physicians and academics will be utilized to strongly position and support the launch of BREVAGen™ and build the Company's sales.

About BREVAGen™The BREVAGen™ breast cancer risk stratification test is a novel genetic test panel that examines a patient's buccal (cheek) swab to detect the absence or presence of certain common genetic variations (SNPs) associated with an increased risk for developing breast cancer. The test is designed to help physicians assess aggregate breast cancer risk from these genetic markers, together with factors from a standard clinical assessment based on a patient's family and personal history. These factors combine to give a clearer picture of an individual woman's risk of developing breast cancer. The BREVAGen™ test may be especially useful for women at intermediate risk of developing breast cancer, including those who have undergone breast biopsies. The test will provide information that can help physicians recommend alternative courses of action, such as more vigilant, targeted surveillance or preventive therapy, on a personalized patient-by-patient basis.

About Genetic Technologies LimitedGenetic Technologies was an early pioneer in recognizing important new applications for "non-coding" DNA (Deoxyribonucleic Acid).  The Company has since been granted patents in 24 countries around the world, securing intellectual property rights for particular uses of non-coding DNA in genetic analysis and gene mapping across all genes in all species.  Its business strategy is the globa
'/>"/>

SOURCE Genetic Technologies Limited Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related medicine technology :

1. Signal Genetics Announces Commercialization Partnership with NeoGenomics Laboratories for Multiple Myeloma Gene Expression Test
2. USP Hospitales of Spain to Offer Interleukin Genetics Heart Health Test Throughout Its Hospital Network
3. Medco Research Institute® and AssureRx Health Initiate Pilot Program to Evaluate Adoption and Clinical Impact of Pharmacogenetic Testing for Selection of Psychotropic Medications
4. Life Technologies Launches 7500 Fast Dx Real-Time PCR Instrument and 3500 Dx Series Genetic Analyzer in Japan
5. Interleukin Genetics and Metagenics Initiate Research Collaboration
6. Technology Collaboration Between New England Biolabs and Sequenom Delivers First Product for Epigenetics
7. Two Novel Lilly Molecules Target Genetic Mutations That Can Lead to Cancer
8. LABS, Inc. Announces Alliance with Ambry Genetics to Expand Testing Solutions for the Reproductive Health Industry
9. RainDance Technologies and Ambry Genetics Expand Collaboration to Address ADME Analysis
10. JS Genetics Develops New Non-Invasive Test, XCAT-TS, to Help Doctors Diagnose Turner Syndrome
11. WARFARIN Study Launched to Assess Impact of Genetic Testing in Reducing Hospitalizations and Deaths Caused by Warfarin